204 related articles for article (PubMed ID: 17952436)
1. Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction.
Nechushtan H; Pham D; Zhang Y; Morgensztern D; Yi KH; Shin SU; Federoff HJ; Bowers WJ; Tolba KA; Rosenblatt JD
Cancer Immunol Immunother; 2008 May; 57(5):663-75. PubMed ID: 17952436
[TBL] [Abstract][Full Text] [Related]
2. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
[TBL] [Abstract][Full Text] [Related]
3. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
4. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
[TBL] [Abstract][Full Text] [Related]
5. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors.
Huck SP; Tang SC; Andrew KA; Yang J; Harper JL; Ronchese F
Cancer Immunol Immunother; 2008 Jan; 57(1):63-71. PubMed ID: 17609951
[TBL] [Abstract][Full Text] [Related]
6. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
[TBL] [Abstract][Full Text] [Related]
7. Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection.
Petersen CC; Petersen MS; Agger R; Hokland ME
J Immunother; 2006; 29(3):241-9. PubMed ID: 16699367
[TBL] [Abstract][Full Text] [Related]
8. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
9. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.
Ishida A; Tanaka H; Hiura T; Miura S; Watanabe S; Matsuyama K; Kuriyama H; Tanaka J; Kagamu H; Gejyo F; Yoshizawa H
Scand J Immunol; 2007 Nov; 66(5):546-54. PubMed ID: 17953530
[TBL] [Abstract][Full Text] [Related]
10. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
11. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
12. The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses.
Xiao Z; Curtsinger JM; Prlic M; Jameson SC; Mescher MF
Int Immunol; 2007 Jun; 19(6):733-43. PubMed ID: 17545279
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells.
Wall EM; Milne K; Martin ML; Watson PH; Theiss P; Nelson BH
Cancer Res; 2007 Jul; 67(13):6442-50. PubMed ID: 17616705
[TBL] [Abstract][Full Text] [Related]
16. Neonatal CD8+ T cells are slow to develop into lytic effectors after HSV infection in vivo.
Fernandez MA; Evans IA; Hassan EH; Carbone FR; Jones CA
Eur J Immunol; 2008 Jan; 38(1):102-13. PubMed ID: 18081035
[TBL] [Abstract][Full Text] [Related]
17. Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells.
Zheng G; Liu S; Wang P; Xu Y; Chen A
Cancer Res; 2006 Jul; 66(13):6793-9. PubMed ID: 16818656
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro.
Evans R; Kamdar SJ; Duffy TM; Krupke DM; Fuller JA; Dudley ME
Anticancer Res; 1995; 15(2):441-7. PubMed ID: 7763019
[TBL] [Abstract][Full Text] [Related]
19. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor growth in immunocompromised hosts by restoring type-2 immunity using infusion of G-CSF-treated allogeneic CD8+ leukocytes.
Ohmori I; Hayamizu K; Oishi K; Yoshimitsu M; Itamoto T; Asahara T
Cytokine; 2005 Dec; 32(6):255-62. PubMed ID: 16368244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
